Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy
The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
Inosine modulates antitumor immunity: Checkpoint blockade immunotherapy harnesses the immune system to kill cancer cells and has been used with great success to treat certain tumors, but not all cancer patients respond. The efficacy of checkpoint blockade immunotherapy has been shown to depend on the presence of distinct, beneficial bacteria residing in the gut of patients, but how the microbiome mediates such beneficial effects is unclear. Mager et al. found that specific bacteria produce a metabolite called inosine that enhances the effect of checkpoint blockade immunotherapy (see the Perspective by Shaikh and Sears). In mouse models, inosine, together with proinflammatory stimuli and immunotherapy, strongly enhanced the antitumor capacities of T cells in multiple tumor types, including colorectal cancer, bladder cancer, and melanoma. Science , this issue p. 1481 ; see also p. 1427
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Inosine, the purine metabolite of Akkermansia muciniphila and Bifidobacterium pseudolongum (B. pseudolongum), plays a vital role in improving the efficacy of ICI [51].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [51]
In the citing paper
“The inosine-A2AR-cAMP-PKA signaling cascade led to the phosphorylation of cAMP response element-binding protein (pCREB), which upregulated IL12Rβ2 and IFNγ transcription and promoted Th1-cell differentiation and accumulation in the TME [51].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [51]
In the citing paper
“The gut microbial metabolite inosine could improve the efficacy of ICI by acting on adenosine 2A receptor (A2AR) on T lymphocytes in intestinal cancer, bladder cancer, and melanoma mouse models [51].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [51]
In the citing paper
“Moreover, specific gut microbes, such as Bifidobacterium [16, 33, 51, 141], Akkermansia [31, 38], Enterococcus [15, 33, 141], Faecalibacterium [49, 142], and Ruminococcaceae [32], play the role of immune adjuvants in ICI immunotherapy.”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [51]
In the citing paper
“for example, anti-CTLA-4 appears to modify gut barrier integrity 51 and thus could feasibly change microbial compositions”
From A gut microbial signature for combination immune checkpoint blockade across cancer types (2024) · cites this paper as [51]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
DADA2: High–resolution sample inference from Illumina amplicon data
Callahan, B. J., McMurdie, P. J., Rosen, M. J., Han, A. W., Johnson, A. J. A., & Holmes, S. P. (2016) · Nature Methods · doi:10.1038/nmeth.3869 · Cited by 35,698
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
16S ribosomal DNA amplification for phylogenetic study
Weisburg, W. G., Barns, S. M., Pelletier, D. A., & Lane, D. J. (1991) · Journal of Bacteriology · doi:10.1128/jb.173.2.697-703.1991 · Cited by 11,934
Greengenes, a Chimera-Checked 16S rRNA Gene Database and Workbench Compatible with ARB
DeSantis, T. Z., Hugenholtz, P., Larsen, N., Rojas, M., Brodie, E. L., Keller, K., Huber, T., Dalevi, D., Hu, P., & Andersen, G. L. (2006) · Applied and Environmental Microbiology · doi:10.1128/aem.03006-05 · Cited by 10,891
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Kozich, J. J., Westcott, S. L., Baxter, N. T., Highlander, S. K., & Schloss, P. D. (2013) · Applied and Environmental Microbiology · doi:10.1128/aem.01043-13 · Cited by 7,112
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Cited by
Items 501–600 of 1,004
Zhang, J., Sun, R., Lyu, Y., Liu, C., Liu, Y., Feng, Y., Fu, M., Wong, P. J. C., Du, Z., Qiu, T., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54352-5 · Cited by 25
“…how dysregulated nucleotide metabolism affects the tumor microenvironment and immune response, offering potential for enhancing immunotherapy 25,26 Nucleotides and their metabolites can activate the immune system through host receptors, including Toll-like receptors, NOD-like receptors,…”
Innao, V., Allegra, A. G., Musolino, C., & Allegra, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238902 · Cited by 37
Precision Probiotic Medicine to Improve ICB Immunotherapy
Luccia, B. D., & Colonna, M. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0221 · Cited by 24
Zheng, X., Xia, C., Liu, M., Wu, H., Yan, J., Zhang, Z., Huang, Y., Gu, Q., & Li, P. (2024) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-023-12825-5 · Cited by 31
“Concurrently, MTHF supplementation creates a conducive growth environment for specific genera such as Rumincoccus , Fusicatenibac-ter , Prevotella , and Dialister , suggesting a regulatory role of folic acid on gut microbiota composition (Mager et al. 2020; Hezaveh et al. 2022).”
Aged Gut Microbiota Contributes to Cognitive Impairment and Hippocampal Synapse Loss in Mice
Li, M., Ren, J., Bao, Y., Wei, W., Yu, X., He, X., gulisima, M., Sheng, L., Zheng, N., Wan, J., et al. (2025) · Aging Cell · doi:10.1111/acel.70064 · Cited by 27
“…its derived metabolites (e.g., acetate and inosine) have been shown to enhance host antiviral response (Niu et al. 2023), prevent non-alcoholic fatty liver disease-related hepatocellular carcinoma (Song et al. 2023), and modulate response to checkpoint inhibitor immunotherapy (Mager et al. 2020).”
Wekking, D., Silva, C. A. C., Viscò, R., Denaro, N., Lambertini, M., Maccioni, A., Loddo, E., Willard-Gallo, K. E., Scartozzi, M., Derosa, L., et al. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104767 · Cited by 30
Recent research progress and clinical status of immunotherapy for colorectal cancer
Huo, Z., Liu, G., & Li, J. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.06.089 · Cited by 36
“Olsenella sp. [233,268] multiple tumors Helps to enhance the anti-tumor effects of ICIs therapy.”
InfluentialUllah, S., Chen, Y., Wu, C., Abbas, Y., Zhong, Y., Chen, X., Tan, J., Cheng, H., & Li, L. (2025) · RSC Advances · doi:10.1039/d5ra01711d · Cited by 25
Bifidobacteria-derived exopolysaccharide promotes anti-tumor immunity
de Oliveira, R. S., Shupe, A., Krause, T., Richardo, T., Ohland, C., Sabachvili, M., Bucher, K., Hetzer, J., Hörner, S., Dauch, D., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116223 · Cited by 24
Self-citationDirecting T-Cell Immune Responses for Cancer Vaccination and Immunotherapy
Smith, P. L., Piadel, K., & Dalgleish, A. G. (2021) · Vaccines · doi:10.3390/vaccines9121392 · Cited by 24
Cheng, Y., Ling, F., Li, J., Chen, Y., Xu, M., Li, S., & Zhu, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1190850 · Cited by 26
“pseudolongum promotes the activation of antitumor Th1 cells through T-cell–specific A2A receptor signaling in response to ICIs immunotherapy (47).”
BackgroundWang, W., Fan, J., Zhang, C., Huang, Y., Chen, Y., Fu, S., & Wu, J. (2024) · Microbiological Research · doi:10.1016/j.micres.2024.127668 · Cited by 25
Cutibacterium acnes‐derived extracellular vesicles promote tumor growth in renal cell carcinoma
Jingushi, K., Kawashima, A., Tanikawa, S., Saito, T., Yamamoto, A., Uemura, T., Sassi, N., Ishizuya, Y., Yamamoto, Y., Kato, T., et al. (2024) · Cancer Science · doi:10.1111/cas.16202 · Cited by 23
A graph neural network approach for predicting drug susceptibility in the human microbiome
Maryam, M., Rehman, M. U., Hussain, I., Tayara, H., & Chong, K. T. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.108729 · Cited by 30
Gut Microbial Signatures in Sporadic and Hereditary Colorectal Cancer
Mori, G., & Pasca, M. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031312 · Cited by 29
Zhang, W., Jin, C., Liu, S., Wan, X., Li, Y., Liu, J., Duan, Z., Ma, J., & Gao, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1757513 · Cited by 22
“Similarly, inosine, a purine-derived metabolite produced by certain bene fi cial commensal bacteria such as Bi fi dobacterium pseudolongum, exerts context-dependent immunomodulatory effects that can enhance antitumor immunity (121).”
Dominguez, D. A., WONG, P. W. K., & Melstrom, L. G. (2024) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-22-526 · Cited by 24
“Additionally, the enrichment of particular bacterial species, such as Bifidobacterium pseudolongum , Lactobacillus johnsonii , and Olsenella , have been shown to significantly improve immune checkpoint inhibitors efficacy in mouse models in multiple tumor types (115).”
Bano, Y., Shrivastava, A., Shukla, P. K., Chaudhary, A. A., Khan, S.-U.-D., & Khan, S. (2024) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2024.2324864 · Cited by 23
“B. pseudolongum is marked immune-booster upregulated the Dc-dependent t-cell circuitry during immunotherapies (Mager et al. 2020).”
Chen, L., Li, B., Zu, M., Reis, R. L., Kundu, S. C., & Xiao, B. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.06.012 · Cited by 24
The cure from within? a review of the microbiome and diet in melanoma
Kumar, P. R., Brazel, D., DeRogatis, J. M., Goldstein, J. B., Whiteson, K., Chow, W. A., Tinoco, R., & Moyers, J. T. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10029-3 · Cited by 25
“cultured intratumoral microbes and found that colonizing germ-free mice with Bifidobacterium pseudolongum, Lactobacillus johnsonii, or Olsenella promoted anti-CTLA-4 responses and tumor control [47].”
BackgroundGut Microbiota and Immunotherapy
Xu, X., & Ying, J. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.945887 · Cited by 25
Xia, C., Cai, Y., Ren, S., & Xia, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1051330 · Cited by 22
The lung, the niche, and the microbe: Exploring the lung microbiome in cancer and immunity
Huynh, M., Crane, M. J., & Jamieson, A. M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1094110 · Cited by 25
“This bacterium was identified as essential in upregulating DC-dependent T cell circuitry, thereby boosting the efficacy of the immunotherapies (123).”
BackgroundCrosstalk between gut microbiota and RNA N6-methyladenosine modification in cancer
Su, H., Cheung, H., Lau, H. C.-H., Chen, H., Zhang, X., Wang, Y., Wang, Y., Chan, M. T. V., Wu, W. K. K., & Chen, H. (2023) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuad036 · Cited by 25
Li, L., Wu, L., Jiang, T., Liang, T., Yang, L., Li, Y., Gao, H., Zhang, J., Xie, X., & Wu, Q. (2023) · Nutrients · doi:10.3390/nu15184002 · Cited by 24
“found a significant decrease in the abundance of Colidextribacter in early and middle colorectal cancer [35].”
BackgroundFrom the Colon to the Liver: How Gut Microbiota May Influence Colorectal Cancer Metastatic Potential
Mignini, I., Piccirilli, G., Galasso, L., Termite, F., Esposto, G., Ainora, M. E., Gasbarrini, A., & Zocco, M. A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020420 · Cited by 26
“Finally, they conclude that the ICI-promoting effect of B. pseudolongum and L. johnsonii was mediated by inosine and hypoxanthine and collectively was dependent on T cell expression of the adenosine A2A receptor [110].”
BackgroundMa, Y., Wei, X., Peng, J., Wei, F., Wen, Y., Liu, M., Song, B., Wang, Y., Zhang, Y., & Peng, T. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1414675 · Cited by 22
Microbial metabolite boosts immunotherapy
Bird, L. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-00465-z · Cited by 22
Yang, J., Xiong, P., Bai, L., Zhang, Z., Zhou, Y. C., Chen, C., Xie, Z., Xu, Y., Chen, M., Wang, H., et al. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.765414 · Cited by 26
“The balance of gut microbiota helps to maintain the biological barrier of the intestine (55).”
BackgroundHow does the gut microbiome influence immune checkpoint blockade therapy?
Almonte, A. A., Rangarajan, H., Yip, D., & Fahrer, A. M. (2021) · Immunology & Cell Biology · doi:10.1111/imcb.12423 · Cited by 21
“In preparing this review, we noticed all key papers used the same antibiotic cocktail to deplete the microbiome of their mouse models and they all use C57BL/6 mice.(9,30,34,35) We have not been able to replicate these experiments in BALB/c mice as they will not drink the published antibiotic cocktail.”
BackgroundMethodInfluentialHan, Q., Li, J., Li, Z. Y., Aishajiang, R., & Yu, D. N. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101601 · Cited by 32
“Mager et al. showed that Bifidobacterium pseudolongum , Lactobacillus johnsonii , and Eubacterium hallii enhanced the efficacy of ICIs in a CRC mouse model [120].”
Exploring effects of gut microbiota on tertiary lymphoid structure formation for tumor immunotherapy
Liu, Y., Li, F., Wang, J., & Yang, R. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1518779 · Cited by 24
“The inosine was a purine metabolite of Akkermansia muciniphila and Bi fi dobacetrium pseudolongum (77).”
InfluentialZhao, S., Lu, Z., Zhao, F., Tang, S., Zhang, L., & Feng, C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1538969 · Cited by 32
Halpin-Veszeleiova, K., Mallouh, M. P., Williamson, L. M., Apro, A. C., Botticello-Romero, N. R., Bahr, C., Shin, M., Ward, K. M., Rosenberg, L., Ritov, V. B., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.174675 · Cited by 205
“Moreover, recent studies have shown that some of these purine metabolites can be immunosuppressive on their own and alter signaling through adenosine receptors (63, 64).”
Current Adenosinergic Therapies: What Do Cancer Cells Stand to Gain and Lose?
Kotulová, J., Hajdúch, M., & Džubák, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212569 · Cited by 23
“Although inosine is predominantly associated with immunosuppressive actions similar to eADO, in this case, inosine stimulate naïve T cells toward Th1 via A2AR-cAMP-PKA-pCREB circuitry specific for intestinal T-cells and thus enhances the efficacy of ICI therapy [212,213].”
BackgroundDiet-gut microbial interactions influence cancer immunotherapy
Wang, X., & Geng, S.-T. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1138362 · Cited by 23
“Bifidobacterium pseudolongum and Bacteroides fragilis stimulated Th1 immune response to enhance ICI efficacy (122, 142).”
BackgroundInfluentialGut and urinary microbiota: the causes and potential treatment measures of renal cell carcinoma
Yang, J.-W., Wan, S., Li, K., Chen, S., & Yang, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1188520 · Cited by 26
“found that the microbial metabolite adenosine enhances the therapeutic efficacy of ICIs in tumor treatment and may be utilized in the development of microbiota-based adjunctive therapies (50).”
BackgroundMendelian randomization suggests a causal relationship between gut dysbiosis and thyroid cancer
Zhu, F., Zhang, P., Liu, Y., Bao, C., Qian, D., Ma, C., Li, H., & Yu, T. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1298443 · Cited by 25
Microecological regulation in HCC therapy: Gut microbiome enhances ICI treatment.
Liu, X.-L., Li, S., Ma, K.-X., & Wang, L. (2024) · Biochimica et Biophysica Acta - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167230 · Cited by 20
The gut microbiome modulate response to immunotherapy in cancer
Jiang, S., Kang, Z., Chen, Y., & Fang, J. (2024) · Science China Life Sciences · doi:10.1007/s11427-023-2634-7 · Cited by 22
“In addition, inosine, produced by Bifidobacterium pseudolongum and A . muciniphila , can promote the activation of Th1 cells and anti-tumor immune activity through the A2AR-cAMP-PKA-CREB pathway, which can enhance the therapeutic effect of ICIs in different cancers (Mager et al., 2020).”
Čierniková, S., Ševčíková, A., Novisedláková, M., & Mego, M. (2024) · Cancers · doi:10.3390/cancers16244271 · Cited by 24
“A combination of CpG treatment with the bacterial metabolite inosine, produced by Bifidobacterium pseudolongum , enhanced CTLA-4 efficacy in mice with melanoma and bladder tumors [130].”
Li, J., Ma, Y., Cao, Y., Zheng, G., Ren, Q., Cheng Ann, C. H. E. N., Zhu, Q., Zhou, Y., Lu, Y., Zhang, Y., et al. (2025) · Nature Microbiology · doi:10.1038/s41564-025-01978-w · Cited by 27
“However, these often focus on general gut microbiome composition without identifying specific taxa 68–70 , or rely on animal models with limited human relevance 72–74 .”
Gao, L., Zhang, Y., Hu, Z. Q., Chen, S., Wang, Q., Zeng, Y., Yin, H., Zhao, J., Zhan, Y., Gao, C., et al. (2025) · Advanced Science · doi:10.1002/advs.202409837 · Cited by 24
Shahid, U. (2025) · The Journal of Precision Medicine Health and Disease · doi:10.1016/j.premed.2025.100018 · Cited by 35
Jayaprakash, M., Kumar, D. V., Chakraborty, G., Chakraborty, A., & Kumar, V. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118559 · Cited by 24
Causative Microbes in Host-Microbiome Interactions
Britton, G. J., & Faith, J. J. (2021) · Annual Review of Microbiology · doi:10.1146/annurev-micro-041321-042402 · Cited by 23
Metabolomics: The Key to Unraveling the Role of the Microbiome in Visceral Pain Neurotransmission
Shute, A., Bihan, D. G., Lewis, I. A., & Nasser, Y. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.917197 · Cited by 23
“Metabolic processes play a fundamental role in all biological processes and an emerging body of literature suggests that host/microbiome dynamics can directly affect immune function (Mager et al., 2020; Yang and Cong, 2021), modulate the clinical presentation of diseases (Chu et al.”
BackgroundSelf-citationZhang, X., Liu, L., Luo, J., & Peng, X. (2022) · Food & Function · doi:10.1039/d2fo01951e · Cited by 20
Cao, Y., Liu, B., Li, W., Geng, F., Gao, X. J., Yue, L., Liu, H., Liu, C., Su, Z., Lü, J., et al. (2023) · MedComm · doi:10.1002/mco2.222 · Cited by 21
The Influence of the Microbiome on Immunotherapy for Gastroesophageal Cancer
Dadgar, N., Keshava, V. E., Raj, M. S., & Wagner, P. L. (2023) · Cancers · doi:10.3390/cancers15184426 · Cited by 21
“…Lactobacillus, Propionibacterium , and Streptococcus thermophilus , in combination with ICIs, can significantly improve the outcomes of cancer patients who receive immunotherapy, by enhancing the efficacy of both CTLA4 and anti-PD-L1 immunotherapy for four different types of cancer [140–142].”
BackgroundRole of the intratumoral microbiome in tumor progression and therapeutics implications
Meng, Y., Fan, Z., Zhou, B., & Zhan, H. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189014 · Cited by 21
Coschi, C. H., & Juergens, R. A. (2023) · Current Oncology · doi:10.3390/curroncol31010001 · Cited by 26
Chen, A., Zhu, J., Liu, R., Mei, Y., Li, L., Fan, Y., Ke, Y., Liu, B., & Liu, Q. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.03.023 · Cited by 37
“Probiotics were found in the human gut, and the antitumor effect of lactis has been proved [13,14].”
BackgroundDang, J., Cai, T., Tuo, Y., Peng, S., Wang, J., Gu, A., Li, J., Ding, L., Du, S., & Wang, L. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c04232 · Cited by 20
Zhao, H., Zhang, W., Lu, Y., Dong, Y., He, Z., Zhen, H., & Li, Q. (2024) · Cancer Medicine · doi:10.1002/cam4.70143 · Cited by 21
“26,33 Furthermore, inosine enhances phytohemagglutinin-mediated immune responses, increases tumor antigen levels, and enhances T-lymphocyte differentiation and proliferation.”
BackgroundYang, B., Guo, X., Shi, C.-Y., Liu, G., Qin, X., Chen, S., Gan, L., Liang, D., Shao, K., Xu, R.-L., et al. (2024) · mSystems · doi:10.1128/msystems.00812-24 · Cited by 21
“In another study, gut-derived inosine was shown to bind to the A 2A receptor on T cells and trigger the A2AR-cAMP-PKA signaling cascade, thus promoting Th1 differentiation and increasing the efficacy of immune checkpoint blockade therapy against tumors (42).”
Lin, A., Shih, C.-T., Chu, H.-F., Chen, C.-W., Cheng, Y.-T., Wu, C.-C., Yang, C. C. H., & Tsai, Y.-C. (2021) · Scientific Reports · doi:10.1038/s41598-021-95659-3 · Cited by 23
Microbial metabolites: novel therapeutic tools for boosting cancer therapies
Luu, M., & Visekruna, A. (2021) · Trends in Cell Biology · doi:10.1016/j.tcb.2021.08.005 · Cited by 20
Gold, A., & Zhu, J. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2125734 · Cited by 20
“Furthermore, inosine was shown to mediate these anti-tumor immune effects only via T cells, as direct administration of inosine to MC38 tumor cells did not alter tumor viability.(19) In conjunction with anti-CLA-4 therapy, inosine and inosineproducing bacterial species were able to, via A2A R-mediated effects on T cel…”
BackgroundMethodInfluentialProgress of Immune Checkpoint Inhibitors Therapy for pMMR/MSS Metastatic Colorectal Cancer
Qu, F., Wu, S., & Yu, W. (2024) · OncoTargets and Therapy · doi:10.2147/ott.s500281 · Cited by 23
“216 Therefore, in order to improve the effectiveness of immunotherapy, the gut microbiome needs to be considered, especially in colorectal cancer, as it is closely related to the gut microbiome.”
Gut microbiota in cancer initiation, development and therapy
Zhang, R., Zhang, X., Lau, H. C.-H., & Yu, J. Q. (2024) · Science China Life Sciences · doi:10.1007/s11427-024-2831-x · Cited by 19
“Further research has demonstrated that inosine from B . pseudolongum influences T cell activation through the adenosine 2A receptor, promoting Th1 cell responses in a context-dependent manner (Mager et al., 2020).”
Interaction between gut microbiota and T cell immunity in colorectal cancer
Jing, Z., Wu, Y., Chu, J., Zhanbo, Q., Wu, X., & Han, S. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103807 · Cited by 20
The gut microbiome enhances breast cancer immunotherapy following bariatric surgery
Bohm, M. S., Joseph, S. C., Sipe, L. M., Kim, M., Leathem, C. T., Mims, T. S., Willis, N., Tanveer, U. A., Elasy, J. H., Grey, E. W., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.187683 · Cited by 22
Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors
Al-Saafeen, B. H., Ali, B. R., & Elkord, E. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1546717 · Cited by 27
“Several other studies have also demonestrated the potential of certain bacterial strains and their metabolites to remarkably in fl uence the therapeutic outcome of ICIs through modulating the TME and promoting T cell activation (155, 156, 170 – 173).”
Engineered bacteria for cancer therapy: Advancements, challenges, and future directions
Wang, M.-G., Liu, M., Wang, D., Yang, D., Zeng, Y., Lan, Y., & Wang, Q. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003807 · Cited by 19
Kleber, K. T., Iranpur, K. R., Perry, L. M., Cruz, S. M., Razmara, A. M., Culp, W. T. N., Kent, M. S., Eisen, J. A., Rebhun, R. B., & Canter, R. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.983344 · Cited by 23
“Some have hypothesized that pet ownership may influence the human gut microbiome as well (70).”
BackgroundLiu, Y., Wang, Q., Liu, H., Niu, J., Jiao, N., Huang, L., Jiang, S., Guan, Q., Yang, W., & Li, Y. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1019130 · Cited by 25
“Colidextribacter can promote the production of inosine which helps reduce the secretion of inflammatory factors (Wang et al., 2019; Mager et al., 2020; Guo et al., 2021).”
BackgroundFecal Microbiota Transplantation as a Cancer Therapeutic
Stoff, R., Wolf, Y., & Boursi, B. (2023) · The Cancer Journal · doi:10.1097/ppo.0000000000000651 · Cited by 23
Interactions of Nanomaterials with Gut Microbiota and Their Applications in Cancer Therapy
Li, X., Wei, H., Qi, J., Ma, K., Luo, Y.-C., & Weng, L. (2023) · Sensors · doi:10.3390/s23094428 · Cited by 22
“Bifidobacterium pseudolongum, Lactobacillus johnsonii, and Olsenella species have also been investigated to assist immunotherapy to achieve tumor suppression or ablation [88].”
BackgroundThe role of extratumoral and intratumoral microorganisms in cancer immunotherapy
Du, Y., Liu, L., Ma, W., Yan, W., Mao, W., Du, Y., Cui, K., Pu, Y., Li, Z., Sansonetti, P. J., et al. (2023) · The Innovation Life · doi:10.59717/j.xinn-life.2023.100016 · Cited by 21
Microbiota: A key factor affecting and regulating the efficacy of immunotherapy
Jiang, Y., Jia, D., Sun, Y., Ding, N., & Wang, L. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1508 · Cited by 22
Emerging tools and best practices for studying gut microbial community metabolism
Noecker, C. A., & Turnbaugh, P. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01074-z · Cited by 25
“Thus, microbial metabolism has far-reaching consequences for host health 4 , influencing infection 5,6 , digestion 7,8 , the immune system 9,10 and cancer treatment outcomes 11,12 , among others.”
Obesity, dysbiosis and inflammation: interactions that modulate the efficacy of immunotherapy
Yende, A. S., & Sharma, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1444589 · Cited by 22
“This interaction improved the ef fi cacy of anti-CTLA4 treatment in mouse models of colorectal, melanoma, and bladder cancer (30).”
BackgroundPurinergic and Adenosinergic Signaling in Pancreatobiliary Diseases
Faraoni, E. Y., Ju, C., Robson, S. C., Eltzschig, H. K., & Bailey, J. M. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.849258 · Cited by 20
Spiliopoulou, P., Vornicova, O., Genta, S., & Spreafico, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021294 · Cited by 20
Gu, Y., Gao, L., He, J., Luo, M., Hu, M. Y., Lin, Y., Li, J., Hou, T., Si, J., & Yu, Y. (2024) · Food & Function · doi:10.1039/d3fo05221d · Cited by 22
Early-life stress and the gut microbiome: A comprehensive population-based investigation
Mulder, R. H., Kraaij, R., Schuurmans, I. K., Francés‐Cuesta, C., Sanz, Y., Medina‐Gómez, C., Duijts, L., Rivadeneira, F., Tiemeier, H. W., Jaddoe, V. W. V., et al. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.02.024 · Cited by 20
“Gut-derived inosine has been shown to be a predictor of immunotherapy effectiveness (Mager et al., 2020).”
BackgroundThe role of the gut microbiome in modulating immunotherapy efficacy in colorectal cancer
Zuo, S., Huang, Y., & Zou, J. (2024) · IUBMB Life · doi:10.1002/iub.2908 · Cited by 23
“9 The gut microbiota can modulate T-cell activity in the tumor microenvironment through its metabolites such as SCFAs, thereby influencing the responsiveness and efficacy of cell therapy.”
Yin, Y., Peng, H., Bai, H., Pei, Z., Chen, Z., Ma, C., Zhu, M., Li, J., Li, C., Gong, Y., et al. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1450690 · Cited by 18
Susiriwatananont, T., Eiamprapaporn, P., Roque, M. V., Farraye, F. A., Pearlman, A., & Chumsri, S. (2025) · Cells · doi:10.3390/cells14221779 · Cited by 21
Araji, G., Maamari, J., Ahmad, F. A., Zareef, R. O., Chaftari, P. S., & Yeung, S. J. (2021) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-21-10 · Cited by 22
“Responder bacteria associated with a positive response to immunotherapy and the proposed mechanisms by which they modulate the anticancer efficacy of ICI therapy Main Responder Bacteria References Checkpoints Targeted Proposed Mechanism Akkermansia A. muciniphila Routy et al, 2018 [55] CTLA-4, PD-1 Stimulate secretion…”
BackgroundInfluentialLeigh, S., Lynch, C. M. K., Bird, B., Griffin, B. T., Cryan, J. F., & Clarke, G. A. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2043849 · Cited by 19
New Developments and Opportunities of Microbiota in Treating Breast Cancers
Meng, Z., Ye, Z., Zhu, P., Zhu, J., Fang, S., Qiu, T., Li, Y., & Meng, L. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.818793 · Cited by 19
“In other tumor models, it was also found that inosine produced by Bifidobacterium pseudolongum can promote Th1 cell differentiation and enhance the effect of immunotherapy mediated by T cell-specific adenosine 2A receptor (A2AR) signaling (Mager et al., 2020).”
BackgroundInfluentialQi, J., Ding, T., Liu, T., Xia, X., Wu, S., Liu, J., Chen, Q., Zhang, D., & Zhao, H. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202204273 · Cited by 19
Citrus Honey Ameliorates Liver Disease and Restores Gut Microbiota in Alcohol–Feeding Mice
Yi, S., Zhang, G., Liu, M., Yu, W., Cheng, G., Luo, L., & Ning, F. (2023) · Nutrients · doi:10.3390/nu15051078 · Cited by 20
“The differential microorganism of MH was Lactobacillus_johnsonii, a probiotic that has been reported to have a potential role in modulating immunotherapy [47].”
BackgroundImmuno-oncology-microbiome axis of gastrointestinal malignancy
Lin, Q., Guan, S.-W., & Yu, H. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i5.757 · Cited by 28
Methionine-producing tumor micro(be) environment fuels growth of solid tumors
Vega, A. A., Marshall, E. A., Noonan, A. J. C., Filho, F. S. L., Yang, J., Stewart, G. L., Johnson, F. D., Vucic, E. A., Pewarchuk, M. E., Shah, P. P., et al. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00832-7 · Cited by 21
Insight into Cancer Immunity: MHCs, Immune Cells and Commensal Microbiota
Wen, M., Li, Y., Qin, X., Qin, B., & Wang, Q. A. (2023) · Cells · doi:10.3390/cells12141882 · Cited by 21
Microbes mediated immunogenic cell death in cancer immunotherapy
Huang, J., Duan, F., Xie, C., Xu, J., Zhang, Y., Wang, Y., Tang, Y., & Leung, E. L. (2023) · Immunological Reviews · doi:10.1111/imr.13261 · Cited by 20
“38 Interestingly, the sensitization of Akkermansia muciniphila to ICIs response can also be attributed to inosine-A 2A R signaling.”
BackgroundDravillas, C. E., Coleman, S. S., Hoyd, R., Caryotakis, G., Denko, L., Chan, C. H. F., Churchman, M. L., Denko, N. C., Dodd, R. D., Eljilany, I., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0170 · Cited by 21
Bouferraa, Y., Chedid, A., Amhaz, G., Lakkiss, A. E., Mukherji, D., Temraz, S. N., & Shamseddine, A. I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158036 · Cited by 18
“Inosine and its metabolite hypoxanthine translocate into the systemic circulation and provoke the differentiation of the Th1 cells through the inosine-A2AR-cAMP-PKA pathway [60].”
BackgroundInfluentialImpact of the ileal microbiota on colon cancer
Roberti, M. P., Rauber, C., Kroemer, G., & Zitvogel, L. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.09.016 · Cited by 18
Late-Stage Glioma Is Associated with Deleterious Alteration of Gut Bacterial Metabolites in Mice
Herbreteau, A., Aubert, P., Croyal, M., Naveilhan, P., Billon‐Crossouard, S., Neunlist, M., Delneste, Y., Couez, D., & Aymeric, L. (2022) · Metabolites · doi:10.3390/metabo12040290 · Cited by 19
“More specifically, bacterial metabolites such as bile acids [18,19], inosin [20], adenosine derivatives [21], and SCFA [22] are key beneficial or deleterious mediators in cancer development or treatment.”
Background‘Know thyself’ – host factors influencing cancer response to immune checkpoint inhibitors
Gunjur, A., Manrique-Rincón, A., Klein, O., Behren, A., Lawley, T. D., Welsh, S. J., & Adams, D. J. (2022) · The Journal of Pathology · doi:10.1002/path.5907 · Cited by 20
“For example, Mager et al found that both Bifidobacterium pseudolongum and Akkermansia muciniphila might synergise with antiCTLA4 efficacy through their common production of inosine, which might help to shift tumour-associated CD4 T cells to a Th1 (anti-tumour) phenotype by agonism of adenosine receptors [110].”
BackgroundBishop, S. L., Drikic, M., Wacker, S., Chen, Y. Y., Kozyrskyj, A. L., & Lewis, I. A. (2022) · Mucosal Immunology · doi:10.1038/s41385-022-00553-4 · Cited by 19
Self-citationDong, C., Zhou, B., Zhao, B., Lin, K., Tian, Y., Zhang, R., Xie, D., Wu, S., & Yang, L. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.12.006 · Cited by 20
“Mager et al. proved that inosine was the metabolite produced by Am 33 .”
InfluentialSun, H., Wang, T., Jiang, X., Li, M., He, X., Ma, Y., Li, X., Jin, W., & Jiao, Z. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02412-9 · Cited by 19
“For instance, inosine was once considered an inhibitor of T helper 1 cells (Th1) differentiation; however, in the presence of exogenous IFN-γ and co-stimulation, inosine promotes Th1 differentiation [130, 131].”
Intratumoral microbiota remodeling of the tumor microenvironment impact solid tumor immunotherapy
Jia, J., Gao, W., Wang, C., Liu, L., Li, Y., Sun, Z., Yang, C., Chen, Y., Yu, H., & Cheng, Y. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08211-w · Cited by 21
“Recent research has indicated that the intratumoral microbiota (or its metabolites) may improve the effectiveness of PDAC immunotherapy [28, 30, 56, 69, 102 – 105] (Fig.”
Leveraging beneficial microbiome-immune interactions via probiotic use in cancer immunotherapy
Jani, C., Edwards, K., Bhanushali, C. D., Zheng, X. X., Salazar, A. S., Lopes, G. D. L., Jr., & Watson, D. C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1713382 · Cited by 21
Microbiota regulates intratumoral monocytes to promote anti-tumor immune responses
McCoy, K. D., & Geuking, M. B. (2021) · Cell · doi:10.1016/j.cell.2021.09.024 · Cited by 17
Self-citation
Metadata
- Authors
- Mager, L. F., Burkhard, R., Pett, N., Cooke, N. C. A., Brown, K., Ramay, H., Paik, S., Stagg, J., Groves, R. A., Gallo, M., Lewis, I. A., Geuking, M. B., & McCoy, K. D.
- Affiliations
- University of Calgary (CA)
- Centre Hospitalier de l’Université de Montréal (CA)
- Corresponding author
- Mager, Lukas F.
- McCoy, Kathy D.
- ORCID
- Venue
- Science
- Published
- 2020-09-18
- Volume
- 369
- Issue
- 6510
- Pages
- 1481-1489
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W3049052172
- Semantic Scholar
- 041ece73120d89c36e2870fa3f1b95b4ebdafab2
- Cited by
- 1,407
- References
- 65
- Citations by year
- 2026: 240 · 2025: 280 · 2024: 260 · 2023: 247 · 2022: 220 · 2021: 134 · 2020: 25
- FWCI
- 56.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (PJT-165930, PJT-156073)
- Natural Sciences and Engineering Research Council of Canada
- Swiss National Science Foundation
- Alberta Innovates
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- inosine, gut microbiota, immune checkpoint inhibitors, cancer immunotherapy, antitumor immunity, microbial metabolites, T cell activation, colorectal cancer, bladder cancer, melanoma, immunotherapy response
- MeSH terms
- Gastrointestinal Microbiome, Lactobacillus johnsonii, Animals, Antibodies, Bifidobacterium, Urinary Bladder Neoplasms, Female, Immunotherapy, Inosine, Intestinal Neoplasms, Male, Melanoma, Mice, Inbred C57BL, Neoplasms, Experimental, Skin Neoplasms, T-Lymphocytes, Receptor, Adenosine A2A, Mice, B7-H1 Antigen, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.